drugset / Trial / NCT06331845
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic chemotherapy (SC).
Timeline
- Start
- 2024-05-01
- Primary completion
- 2026-05-01
- Completion
- 2028-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1 g | — |
| Subject | Capecitabine | Small molecule | 1.25 g | — |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 100 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |